RecruitingPhase 1NCT07424833

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

Sponsor

Ascentage Pharma Group Inc.

Enrollment

180 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Hematological Malignancies Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)Relapsed/Refractory Mantle Cell Lymphoma (MCL)Relapsed/Refractory Waldenström Macroglobulinemia (WM)Relapsed/Refractory Marginal Zone Lymphoma (MZL)Relapsed/Refractory Follicular Lymphoma (FL)

Summary

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called APG-3288 for people with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (cll/sll, relapsed/refractory diffuse large b-cell lymphoma (dlbcl; including richter transformation), and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAPG-3288

Orally administered daily; 28 days per cycle.

Locations(6)

START Los Angele

Los Angeles, California, United States

Mayo Clinic

Jacksonville, Florida, United States

START Midwest

Grand Rapids, Michigan, United States

START New Jersey

East Brunswick, New Jersey, United States

The University of TX MD Anderson Cancer Center

Houston, Texas, United States

Henan Cancer Hospital

Zhengzhou, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07424833

Related Trials

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

NCT055288871 location